pamidronate and osteoprotegerin

pamidronate has been researched along with osteoprotegerin in 35 studies

Research

Studies (35)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (57.14)	29.6817
2010's	14 (40.00)	24.3611
2020's	1 (2.86)	2.80

Authors

Authors	Studies
Tricot, G	1
Choong, PF; Fisher, JL; Mackie, PS; Zhou, H	1
Choung, PH; Myoung, H; Park, JY	1
Blaschke, S; Emons, G; Frosch, KH; Gründker, C; Hofbauer, LC; Lauck, V; Viereck, V	1
Dunstan, CR; Haralambous, S; Hayer, S; Kollias, G; Lang, S; Maier, A; Pietschmann, P; Redlich, K; Schett, G; Smolen, JS; Steiner, G; Tohidast-Akrad, M; Türk, B; Woloszczuk, W	1
Jeong-Hwa, B; Kim, GS; Kim, YH	1
Berenson, JR	1
Lipton, A	1
Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD	1
de la Fuente, J; Goldman, JM; Hatjiharissi, E; Meletis, J; Rahemtulla, A; Szydlo, R; Terpos, E; Viniou, N; Yataganas, X	1
Loukopoulos, D; Loutradi, A; Palermos, J; Rahemtulla, A; Spina, G; Terpos, E; Voskaridou, E	1
Angelopoulou, MK; Dimopoulou, MN; Gribabis, DA; Kokoris, SI; Kyrtsonis, MC; Pangalis, GA; Siakantaris, MP; Vassilakopoulos, TP	1
Barken, I; Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hoffman, RM; Jiang, P; Yang, M	1
Adamu, S; Asuncion, F; Capparelli, C; Dunstan, CR; Geng, Z; Grisanti, M; Kostenuik, PJ; Morony, S; Starnes, C; Tan, HL; Warmington, K; Weimann, B	1
Kananen, K; Laitinen, K; Ruutu, T; Välimäki, MJ; Volin, L	1
Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hillegonds, DJ; Hoffman, RM; Yang, M	1
Adamopoulos, IE; Athanasou, NA; Edwards, JR; Ferguson, DJ; Wordsworth, PB	1
Avanzati, A; Campagna, S; De Paola, V; Franci, MB; Gennari, L; Martini, G; Merlotti, D; Nuti, R; Salvadori, S; Valleggi, F	1
Darendeliler, MA; Difuria, C; Gagari, E; Grunes, B; Keles, A; Kent, R; Muller, R; Srinivasan, V; Stashenko, P	1
Bajetta, E; Bombardieri, E; De Conno, F; Mariani, L; Martinetti, A; Miceli, R; Ripamonti, C; Seregni, E	1
Darmon, P; Molines, L; Raccah, D	1
Dabbous, MKh; Seshul, BA; Tipton, DA	1
Huang, L; Kumta, SM; Lau, CP; Leung, PY; Ng, PK; Tsui, SK	1
Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D	1
Kwon, YD; Lee, HW; Ohe, JY	1
Ah Kioon, MD; Cohen-Solal, ME; de Vernejoul, MC; Funck-Brentano, T; Hannouche, D; Hay, E; Lin, H; Lioté, F; Nizard, R; Orcel, P; Schiltz, C	1
Karamizadeh, Z; McAlister, WH; Mumm, S; Nasirabadi, S; Saki, F; Whyte, MP	1
Jabłoński, M; Matuszewska, A; Matuszewski, Ł; Mazurkiewicz, T; Polkowska, I; Turżańska, K	1
Chen, JY; Chen, XY; Fan, YX; Guo, KJ; Li, Q; Lv, Y; Xia, JY; Yan, HC; Yang, HS; Zhao, H	1
Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G	1
Balbontín-Ayala, F; Cañigral, A; Carlos, Fd; Cobo, T; Fernández-González, FJ; Fernández-Vázquez, JP; Gonzalo-Orden, JM; Sánchez-Lasheras, F; Vega, JA	1
Dela Cruz, A; Grynpas, MD; Mitchell, J	1
Cunha, FQ; de Paula, FJA; Dick-de-Paula, I; Fukada, SY; Jordão, AA; Jorgetti, V; Nogueira-Barbosa, MH; Ramalho, LNZ; Spirlandeli, AL; Volpon, JB; Zamarioli, A	1
Alikasifoglu, A; Buyukyilmaz, G; Gonc, EN; Kandemir, N; Ozon, A; Simsek, OP	1
Grasemann, C; Hauffa, BP; Heyer, CM; Höppner, J; Lobert, F; Steff, K	1

Reviews

6 review(s) available for pamidronate and osteoprotegerin

Article	Year
New insights into role of microenvironment in multiple myeloma. Lancet (London, England), 2000, Jan-22, Volume: 355, Issue:9200 Topics: Antineoplastic Agents; Carrier Proteins; Cytokines; Diphosphonates; Glycoproteins; Humans; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor	2000
Advances in the biology and treatment of myeloma bone disease. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17 Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid	2002
Bisphosphonates and metastatic breast carcinoma. Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycoproteins; Humans; Imidazoles; Infusions, Intravenous; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid	2003
Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes & metabolism, 2010, Volume: 36, Issue:4 Topics: Alendronate; Arthropathy, Neurogenic; Biomarkers; Bone Density Conservation Agents; Calcitonin; Diabetic Foot; Diagnosis, Differential; Diphosphonates; Early Diagnosis; Foot Deformities, Acquired; Foot Injuries; Humans; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; RANK Ligand; Weight-Bearing	2010
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer treatment reviews, 2015, Volume: 41, Issue:2 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid	2015
Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review. Dental press journal of orthodontics, 2015, Volume: 20, Issue:5 Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Remodeling; Celecoxib; Clodronic Acid; Diclofenac; Diphosphonates; Humans; Imidazoles; Interferon-gamma; Isoxazoles; Lactones; Mice; Orthodontic Anchorage Procedures; Osteoclasts; Osteoprotegerin; Pamidronate; Rats; Resveratrol; Stilbenes; Sulfones; Tooth Mobility; Tooth Movement Techniques; Zoledronic Acid	2015

Trials

3 trial(s) available for pamidronate and osteoprotegerin

Article	Year
Bisphosphonates and metastatic breast carcinoma. Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycoproteins; Humans; Imidazoles; Infusions, Intravenous; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid	2003
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycoproteins; Humans; Male; Middle Aged; Multiple Myeloma; Osteoprotegerin; Pamidronate; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Treatment Outcome	2003
Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:5 Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Resorption; Case-Control Studies; Diphosphonates; Female; Hip; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoprotegerin; Pamidronate; RANK Ligand; Stem Cell Transplantation; Transplantation, Homologous	2006

Other Studies

27 other study(ies) available for pamidronate and osteoprotegerin

Article	Year
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. British journal of cancer, 2001, Apr-06, Volume: 84, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carrier Proteins; Cell Division; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glycoproteins; Growth Inhibitors; Membrane Glycoproteins; Osteoprotegerin; Osteosarcoma; Pamidronate; RANK Ligand; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Tumor Cells, Cultured	2001
Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. Journal of periodontal research, 2001, Volume: 36, Issue:4 Topics: Acid Phosphatase; Alkaline Phosphatase; Analysis of Variance; Animals; Bone and Bones; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Remodeling; Bone Transplantation; Diphosphonates; Female; Gene Expression; Glycoproteins; Isoenzymes; Osteocalcin; Osteoprotegerin; Pamidronate; Rats; Rats, Sprague-Dawley; Receptors, Calcitonin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skull; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Transforming Growth Factor beta; Up-Regulation	2001
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochemical and biophysical research communications, 2002, Mar-01, Volume: 291, Issue:3 Topics: Biomarkers; Cell Differentiation; Cells, Cultured; Collagen Type I; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Glucocorticoids; Glycoproteins; Humans; Imidazoles; Kinetics; Osteoblasts; Osteoprotegerin; Pamidronate; Protein Biosynthesis; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Transcriptional Activation; Zoledronic Acid	2002
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis and rheumatism, 2002, Volume: 46, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis; Arthrography; Buffers; Cell Count; Diphosphonates; Drug Therapy, Combination; Glycoproteins; Humans; Infliximab; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Pamidronate; Phosphates; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Sodium Chloride; Tumor Necrosis Factor-alpha	2002
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Experimental & molecular medicine, 2002, May-31, Volume: 34, Issue:2 Topics: Alendronate; Animals; Bone Resorption; Carrier Proteins; Cells, Cultured; Diphosphonates; Gene Expression Regulation; Glycoproteins; Membrane Glycoproteins; Mice; Mice, Inbred ICR; Osteoblasts; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction	2002
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. International journal of cancer, 2003, Sep-01, Volume: 106, Issue:3 Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Biomarkers, Tumor; Bone Neoplasms; C-Reactive Protein; Cytarabine; Dexamethasone; Diphosphonates; Female; Glycoproteins; Humans; Interleukin-6; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoclasts; Osteogenesis; Osteoprotegerin; Pamidronate; Paraproteins; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reference Values; Sensitivity and Specificity; Tartrate-Resistant Acid Phosphatase; Vincristine	2003
Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. British journal of haematology, 2003, Volume: 123, Issue:4 Topics: Acid Phosphatase; Adult; Alkaline Phosphatase; Anti-Inflammatory Agents; beta-Thalassemia; Biomarkers; Blood Transfusion; Bone Density; Carrier Proteins; Case-Control Studies; Collagen; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Glycoproteins; Humans; Isoenzymes; Lumbar Vertebrae; Male; Membrane Glycoproteins; Middle Aged; Osteocalcin; Osteoporosis; Osteoprotegerin; Pamidronate; Peptides; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase	2003
Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. European journal of haematology, 2004, Volume: 72, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Bone Resorption; Cyclophosphamide; Dexamethasone; Diphosphonates; Doxorubicin; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Glycoproteins; Humans; Life Tables; Male; Melphalan; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasm Staging; Neovascularization, Pathologic; Osteoprotegerin; Pamidronate; Prednisone; Prognosis; Proteoglycans; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Survival Analysis; Syndecan-1; Syndecans; Vincristine	2004
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. The Prostate, 2005, Feb-15, Volume: 62, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Calcium; Carrier Proteins; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Glycoproteins; Green Fluorescent Proteins; Humans; Interleukin-6; Interleukin-8; Male; Membrane Glycoproteins; Mice; Mice, SCID; Microscopy, Fluorescence; Osteoprotegerin; Pamidronate; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; Radiography; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Transduction, Genetic	2005
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology, 2005, Volume: 146, Issue:8 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Diphosphonates; Disease Models, Animal; Glycoproteins; Humans; Hypercalcemia; Ligands; Membrane Glycoproteins; Mice; NF-kappa B; Osteoprotegerin; Pamidronate; Parathyroid Hormone-Related Protein; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor	2005
The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-15, Volume: 12, Issue:8 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Disease Progression; Glycoproteins; Green Fluorescent Proteins; Humans; Male; Mice; Mice, Nude; Osteoprotegerin; Pamidronate; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays	2006
Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis. Human pathology, 2006, Volume: 37, Issue:9 Topics: Adult; Anti-Inflammatory Agents; Arthritis; Bone Resorption; Carrier Proteins; Cell Differentiation; Cells, Cultured; Cytokines; Diphosphonates; Glycoproteins; Histiocytosis, Non-Langerhans-Cell; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Macrophages; Male; Membrane Glycoproteins; Methylprednisolone; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Skin Diseases; Synovial Fluid; Tumor Necrosis Factor-alpha	2006
Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone, 2007, Volume: 40, Issue:2 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Humans; Male; Middle Aged; Osteitis Deformans; Osteoprotegerin; Pamidronate; RANK Ligand	2007
Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force. European journal of oral sciences, 2007, Volume: 115, Issue:2 Topics: Animals; Apoptosis; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Mice; Models, Animal; Molar; Osteoclasts; Osteoprotegerin; Pamidronate; Time Factors; Tooth Movement Techniques	2007
Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response? Oncology reports, 2007, Volume: 17, Issue:6 Topics: Adult; Aged; Alkaline Phosphatase; Analgesics; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Bone Remodeling; Collagen Type I; Diphosphonates; Female; Humans; Male; Middle Aged; Osteocalcin; Osteopontin; Osteoprotegerin; Pamidronate; Peptide Fragments; Peptides; Procollagen; Prognosis	2007
Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. Journal of periodontal research, 2011, Volume: 46, Issue:1 Topics: Alendronate; Analysis of Variance; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Diphosphonates; Fibroblasts; Gingiva; Humans; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Necrosis; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Statistics, Nonparametric	2011
Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2011, Volume: 29, Issue:3 Topics: Alkyl and Aryl Transferases; Apoptosis; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Caspases; Cell Division; Cell Survival; Diphosphonates; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Gene Expression; Giant Cell Tumor of Bone; Humans; Methionine; Osteoprotegerin; Pamidronate; Prenylation; RANK Ligand; RNA, Messenger; S Phase; Tumor Cells, Cultured	2011
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. International journal of oral and maxillofacial surgery, 2011, Volume: 40, Issue:6 Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytochrome P-450 CYP2C8; Diphosphonates; Female; Gene Frequency; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Matrix Metalloproteinase 2; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopontin; Osteoprotegerin; Pamidronate; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor Activator of Nuclear Factor-kappa B; Risk Factors; Smoking; Time Factors; Tumor Necrosis Factor-alpha; Zoledronic Acid	2011
Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clinical oral investigations, 2012, Volume: 16, Issue:4 Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Culture Techniques; Cell Differentiation; Culture Media; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); Humans; Macrophage Colony-Stimulating Factor; Male; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteogenesis; Osteoprotegerin; Pamidronate; Real-Time Polymerase Chain Reaction; Time Factors; Young Adult	2012
Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PloS one, 2012, Volume: 7, Issue:3 Topics: ADAM Proteins; ADAMTS5 Protein; Animals; Bone and Bones; Bone Diseases, Metabolic; Bone Resorption; Cartilage; Diphosphonates; Estradiol; Female; Humans; Menisci, Tibial; Mice; Mice, Inbred C57BL; Osteoarthritis; Osteoprotegerin; Pamidronate; Protective Agents	2012
Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:6 Topics: Adult; Amino Acid Substitution; Bone Density Conservation Agents; Child, Preschool; Craniosynostoses; Diphosphonates; Female; Homozygote; Humans; Iran; Male; Mutation, Missense; Osteitis Deformans; Osteoprotegerin; Pamidronate; Pedigree; RANK Ligand; Vitamin D; Vitamin D Deficiency	2013
Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using micro-computed tomography. International orthopaedics, 2013, Volume: 37, Issue:6 Topics: Animals; Bone Cements; Bone Density Conservation Agents; Diphosphonates; Male; Models, Animal; Osteogenesis; Osteoprotegerin; Pamidronate; RANK Ligand; Rats; Rats, Wistar; Tibia; X-Ray Microtomography	2013
Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC musculoskeletal disorders, 2014, Nov-06, Volume: 15 Topics: Animals; Bone Density Conservation Agents; Cartilage, Articular; Diphosphonates; Gene Expression Regulation; Osteoarthritis; Osteoprotegerin; Pamidronate; Rabbits; Random Allocation; RANK Ligand; Treatment Outcome	2014
Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate. American journal of physiology. Endocrinology and metabolism, 2016, 05-15, Volume: 310, Issue:10 Topics: Absorptiometry, Photon; Angiotensin II; Animals; Bone Density; Bone Density Conservation Agents; Bone Marrow Cells; Bone Resorption; Cancellous Bone; Coculture Techniques; Diphosphonates; Femur; GTP-Binding Protein alpha Subunits, Gq-G11; Macrophage Colony-Stimulating Factor; Mice; Mice, Transgenic; Osteoblasts; Osteogenesis; Osteoprotegerin; Pamidronate; RANK Ligand; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2016
Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment. Clinics (Sao Paulo, Brazil), 2017, Volume: 72, Issue:4 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Carbon Tetrachloride; Core Binding Factor Alpha 1 Subunit; Diphosphonates; Disease Models, Animal; Liver Cirrhosis; Liver Diseases; Male; Mice, Inbred C57BL; Osteoprotegerin; Pamidronate; Phosphorus; RANK Ligand; Tartrate-Resistant Acid Phosphatase; X-Ray Microtomography	2017
Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, Volume: 29, Issue:6 Topics: Bone Density Conservation Agents; Drug Resistance; Drug Substitution; Gene Deletion; Humans; Infant; Male; Osteitis Deformans; Osteoprotegerin; Pamidronate; Radiography; Zoledronic Acid	2018
Rhizomelia and Impaired Linear Growth in a Girl with Juvenile Paget Disease: The Natural History of the Condition. Hormone research in paediatrics, 2021, Volume: 94, Issue:3-4 Topics: Adolescent; Child; Child, Preschool; Denosumab; Female; Femur; Growth Plate; Humans; Humerus; Osteitis Deformans; Osteoprotegerin; Pamidronate	2021